UK markets close in 7 hours 24 minutes
  • FTSE 100

    7,003.90
    +40.57 (+0.58%)
     
  • FTSE 250

    22,211.99
    +142.68 (+0.65%)
     
  • AIM

    1,225.92
    +1.08 (+0.09%)
     
  • GBP/EUR

    1.1605
    -0.0021 (-0.18%)
     
  • GBP/USD

    1.4063
    +0.0012 (+0.08%)
     
  • BTC-GBP

    35,653.01
    -573.34 (-1.58%)
     
  • CMC Crypto 200

    1,384.05
    -3.85 (-0.28%)
     
  • S&P 500

    4,112.50
    +49.46 (+1.22%)
     
  • DOW

    34,021.45
    +433.79 (+1.29%)
     
  • CRUDE OIL

    63.88
    +0.06 (+0.09%)
     
  • GOLD FUTURES

    1,833.80
    +9.80 (+0.54%)
     
  • NIKKEI 225

    28,084.47
    +636.46 (+2.32%)
     
  • HANG SENG

    28,024.64
    +305.97 (+1.10%)
     
  • DAX

    15,226.30
    +26.62 (+0.18%)
     
  • CAC 40

    6,305.84
    +17.51 (+0.28%)
     

Global IVD Market Report 2021 with COVID-19 Impacts (Q3 2020 to Q1 2021)

Research and Markets
·2-min read

Dublin, May 04, 2021 (GLOBE NEWSWIRE) -- The "2021 IVD Market Update and COVID-19 Impact" report has been added to ResearchAndMarkets.com's offering.

This report, 2021 IVD Market Update and COVID-19 Impact, is an update of the market for in vitro diagnostics products from the report's analysts to reflect the latest information.

Key Questions Answered:

  • What is the Size of the IVD Market in 2021?

  • What Impact has COVID-19 Had on IVD Markets?

  • What Major Trends are Affecting the Market in 2021?

As part of its coverage, this report contains market sizing for the following categories of IVD:

  • Clinical Chemistry

  • Immunoassays- non isotopic

  • Infectious disease

  • Other immunos

  • Blood bank screening

  • Drugs of Abuse

  • Diabetes HbA1c - lab

  • Hematology - Core Lab

  • Microbiology (ID/AST)

  • Microbiology (molecular)

  • Microbiology - Mass Spectrometry

  • Radioimmunoassays

  • Coagulation (PT/INR)

  • Coagulation, molecular

  • Histology/cytology

  • HPV, molecular

  • Nucleic acid assays

  • Blood grouping/typing

  • Blood bank molecular

  • NAT Blood Screens

  • Circulating tumor cells

  • POC, OTC diabetes

  • POC, OTC other

  • POC, professional/hospital;

  • COVID 19

Complete market figures and forecasts will be part of the Worldwide report in August.

How is COVID-19 Impacting the Market in 2021

This report does detail the effects of COVID-19 including the following:

  • Effect of COVID-19 on Market Segments

  • IVD Market excluding and with COVID-19, 2020

  • IVD Market Distribution by Segment

  • Global In Vitro Diagnostic Market - YoY Growth 2019-2020

  • Global In Vitro Diagnostic Market - YoY Growth 2019-2020

  • IVD Segment Performance, Q1 2020 - Q4 2020

  • IVD Segment Performance, Total Market Value, 2020

Also included in this report:

  • Product Trends and Developments

  • COVID-19 Developments Sept. 2020 to Feb 2021

  • Select IVD Market Participant Developments

  • Competitive Leader Updates

Key Topics Covered:

ONE: WORLDWIDE IVD MARKET - 2020 UPDATE

COVID 19

IVD MARKET HIGHLIGHTS AND EFFECTS OF COVID-19

  • Effect of COVID-19 on Market Segments

TWO: PRODUCT TRENDS AND NEW DEVELOPMENTS

  • NEW CORE IVD PRODUCT LAUNCHES AND DEVELOPMENTS

    • Clinical Chemistry

    • Hematology

    • Oncology

    • Coagulation

    • Immunoassay

    • Microbiology

    • Histology

    • Molecular Specialties

    • POC

    • Mass Spectrometry

  • COVID-19 DEVELOPMENTS - SEPTEMBER 2020 - FEBRUARY 2021

  • Antigen

  • Serology

  • Molecular

THREE: SELECTED IVD MARKET PARTICIPANT DEVELOPMENTS

  • SELECTED COMPETITIVE LEADER UPDATES

    • IVD Segment Growth by Leading Competitors, Change in Sales 2019-2020

    • Changes in Market Distribution for IVD Sales, 2019-2020 - Roche Maintains Lead, Abbott Closing Gap

  • Abbott

  • Aidian Oy

  • Becton Dickinson and Co

  • Biomerieux SA

  • Danaher

  • Hologic, Inc.

  • Illumina

  • Ortho Clinical Diagnostics

  • Perkin Elmer

  • Quidel Corporation

  • Roche Diagnostic

  • Thermo Fisher Scientific

FOUR: NEW OPPORTUNITIES

  • Telehealth and Remote Patient Monitoring

  • Expanding Options in Reimbursement

  • POC

For more information about this report visit https://www.researchandmarkets.com/r/9mobgz

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900